Inhaled and local anesthetics

Inhaled and local anesthetics

Drug monograph · NCLEX study reference
Therapeutic class	Anesthetic
Pharmacologic class	Volatile inhaled anesthetics; amide local anesthetics
Onset / peak / duration	Inhaled rapid and titratable; local anesthetics minutes to onset with duration by agent (bupivacaine long).
Half-life / level	Variable; no routine level.
Routes	Transdermal, Inhaled, Topical
High-alert (ISMP)	No
Black box warning	None
Antidote / reversal	Dantrolene for malignant hyperthermia; lipid emulsion for local anesthetic systemic toxicity.
Pregnancy / lactation	Used in anesthesia care as needed.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Inhaled and local anesthetics — Anesthetic; Volatile inhaled anesthetics; amide local anesthetics.

Identification

• Therapeutic class: Anesthetic.
• Pharmacologic class: Volatile inhaled anesthetics; amide local anesthetics.

Pharmacology

• Mechanism of action: Inhaled agents produce general anesthesia through central depression; local anesthetics block sodium channels to stop nerve conduction in a region.
• Onset / peak / duration: Inhaled rapid and titratable; local anesthetics minutes to onset with duration by agent (bupivacaine long).
• Half-life / therapeutic level: Variable; no routine level.

Clinical use

• Indications: General anesthesia (inhaled), local and regional anesthesia and nerve blocks (local), lidocaine also as an antiarrhythmic and topical.
• Usual dose, route, frequency: Inhaled by anesthesia provider; local by injection, topical, or patch.
• Maximum dose / adjustments: Respect maximum local anesthetic doses (especially bupivacaine, which is cardiotoxic); epinephrine-containing solutions not used in end-arterial areas (fingers, toes, nose, ears).

Safety

• Contraindications: Malignant hyperthermia history (volatile agents are triggers), amide anesthetic allergy.
• Black box warning: None for these prototypes.
• Interactions: Other CNS depressants; local anesthetics with antiarrhythmics (additive cardiac effects).
• Pregnancy / lactation: Used in anesthesia care as needed.
• High-alert: No.

Adverse effects

• Common side effects: Nausea after general anesthesia; local numbness and tingling.
• Serious effects to report: Malignant hyperthermia (volatile agents), local anesthetic systemic toxicity (CNS excitation then seizures, cardiac toxicity), bupivacaine cardiotoxicity.
• Antidote / reversal: Dantrolene for malignant hyperthermia; lipid emulsion for local anesthetic systemic toxicity.

Nursing process

• Assessment before administration: Malignant hyperthermia history, allergies, vital signs.
• Interventions during therapy: Continuous monitoring; have dantrolene available in surgical areas; aspirate before injecting local anesthetic.
• Monitor: Temperature and rigidity (malignant hyperthermia), CNS and cardiac signs.
• Evaluation / expected outcome: Adequate anesthesia.

Patient teaching

• Patient teaching: Report any family history of anesthesia reactions before surgery.
• Notify provider if: Not applicable (monitored setting).
• Administration tips: Monitored settings; respect local anesthetic dose limits.